Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ticlopidine and platelet function].

M Camici1, L Evangelisti

  • 1Istituto Clinica Medica II, Università degli Studi, Pisa.

Minerva Medica
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing intra- and inter-molecular interactions through rotational spectroscopy: The case of the odorant 2'-aminoacetophenone and its 1:1 water and neon complexes.

The Journal of chemical physics·2022
Same author

Ocular involvement in monkeypox: Description of an unusual presentation during the current outbreak.

The Journal of infection·2022
Same author

A 72-h intervention for improvement of the rate of optimal antibiotic therapy in patients with bloodstream infections.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II.

The international journal of biochemistry & cell biology·2015
Same author

The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.

Biochemical pharmacology·2015
Same author

Unexpected death of a ventilator-dependent amyotrophic lateral sclerosis patient.

Revista portuguesa de pneumologia·2013
Same journal

How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

Minerva medica·2026
Same journal

Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

Minerva medica·2026
Same journal

Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

Minerva medica·2026
Same journal

Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

Minerva medica·2026
Same journal

Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

Minerva medica·2026
Same journal

Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

Minerva medica·2026
See all related articles

Ticlopidine improves the prothrombotic state in macular degeneration by reducing platelet aggregation and increasing deaggregation. This antiplatelet action is linked to inhibiting platelet release reactions.

Area of Science:

  • Ophthalmology
  • Hematology
  • Pharmacology

Context:

  • Macular degeneration is an eye disease associated with a prothrombotic state.
  • Platelet behavior and plasma markers are implicated in thrombotic conditions.

Purpose:

  • To investigate the effects of the antiplatelet drug ticlopidine on platelet aggregation, deaggregation, and beta-thromboglobulin levels in patients with macular degeneration.
  • To determine if ticlopidine administration improves the prothrombotic state observed in this patient group.

Summary:

  • Administration of ticlopidine for 15 days significantly reduced in vitro platelet aggregation and ex vivo plasma beta-thromboglobulin levels.
  • Concurrently, thrombocyte deaggregation significantly increased, indicating an improvement in the prothrombotic state.

Related Experiment Videos

  • The study suggests ticlopidine's antiplatelet effect is mediated by the inhibition of platelet release reactions.

    • Impact:

    • Ticlopidine demonstrates potential as a therapeutic agent to counteract the prothrombotic state in macular degeneration.
    • Findings provide insights into the mechanisms of antiplatelet drugs and their role in ophthalmic vascular diseases.
    • This research may inform future strategies for managing patients with macular degeneration and associated thrombotic risks.